b
r
c
viral
respiratori
tract
infect
vrti
signific
caus
morbid
mortal
patient
undergo
allogen
hematopoiet
stem
cell
transplant
allohsct
studi
aim
assess
epidemiolog
characterist
risk
factor
outcom
vrti
occur
period
condit
day
allohsct
era
molecular
test
studi
retrospect
record
review
patient
underw
allohsct
royal
melbourn
hospit
januari
decemb
symptomat
patient
test
use
respiratori
multiplex
polymeras
chain
reaction
pcr
logist
regress
kaplanmei
analysi
use
identifi
risk
factor
vrti
risk
death
intens
care
unit
icu
admiss
respect
total
patient
review
episod
vrti
identifi
patient
rhinoviru
account
major
infect
major
episod
present
initi
upper
respiratori
tract
infect
progress
lower
respiratori
tract
infect
eleven
episod
associ
icu
admiss
death
directli
due
vrti
previou
autolog
hsct
associ
increas
risk
vrti
odd
ratio
confid
interv
risk
death
p
icu
admiss
p
significantli
differ
vrti
statu
vrti
common
first
day
allohsct
associ
icu
admiss
respiratori
virus
rv
includ
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
rsv
rhinoviru
coronaviru
adenoviru
human
metapneumoviru
hmpv
common
caus
viral
respiratori
tract
infect
vrti
previou
studi
shown
rv
caus
signific
morbid
mortal
patient
undergo
hematopoiet
stem
cell
transplant
hsct
particular
allogen
hsct
allohsct
diagnosi
rv
especi
older
studi
depend
mainli
nonmolecular
diagnost
method
includ
direct
antigen
detect
cell
cultur
limit
poor
sensit
molecular
test
use
polymeras
chain
reaction
pcr
allow
rapid
detect
rv
high
sensit
specif
moreov
multiplex
assay
enabl
detect
multipl
rv
singl
test
current
standard
care
mani
clinic
set
purpos
studi
assess
epidemiolog
characterist
risk
factor
outcom
vrti
allohsct
recipi
era
molecular
test
melbourn
hospit
rmh
januari
decemb
first
allohsct
consid
patient
underw
multipl
transplant
studi
period
patient
record
first
day
follow
allohsct
review
demograph
clinic
data
collect
hospit
clinic
record
use
case
report
form
includ
age
sex
underli
diseas
previou
therapi
stem
cell
sourc
condit
therapi
graftversushost
diseas
gvhd
outcom
ie
intens
care
unit
icu
admiss
death
baselin
measur
lymphocyt
neutrophil
level
cytomegaloviru
cmv
seroposit
collect
data
respiratori
viral
pcr
test
result
symptomat
patient
extract
rmh
patholog
databas
patient
rv
infect
number
vrti
type
rv
clinic
present
antivir
therapi
outcom
ie
icu
admiss
death
use
mechan
ventil
progress
lower
respiratori
tract
infect
lrti
also
obtain
period
review
period
treatment
rsv
iv
ribavirin
recommend
set
radiolog
chang
patient
within
day
allohsct
specimen
includ
nasal
throat
swab
nasopharyng
aspir
sputum
bronchoalveolar
lavag
specimen
examin
realtim
pcr
melbourn
health
share
patholog
servic
accord
previous
publish
protocol
rv
includ
multiplex
pcr
panel
rsv
influenza
type
b
rhinoviru
test
copathogen
part
routin
assess
perform
discret
treat
physician
test
includ
convent
cultur
bacteria
fungi
pcr
legionella
pneumocysti
jirovecii
aspergillu
viral
pcr
herp
simplex
viru
hsv
cmv
varicella
zoster
viru
human
herpesviru
hhv
hmpv
adenoviru
bacteri
pcr
mycoplasma
pneumonia
chlamydophila
pneumonia
chlamydia
psittaci
baselin
measur
lymphocyt
neutrophil
defin
measur
obtain
day
admiss
day
lymphopenia
defin
absolut
lymphocyt
count
l
neutropenia
defin
absolut
neutrophil
count
l
condit
intens
defin
accord
center
intern
blood
marrow
transplant
research
guidelin
upper
respiratori
tract
infect
urti
defin
rv
detect
upper
respiratori
tract
fluid
specimen
togeth
symptom
andor
sign
exclus
possibl
caus
lrti
defin
detect
rv
respiratori
secret
preferenti
sampl
obtain
site
involv
togeth
patholog
sputum
product
hypoxia
pulmonari
infiltr
progress
lrti
defin
onset
lrti
patient
previou
urti
episod
infect
defin
evid
rv
urti
lrti
detect
condit
period
day
follow
allohsct
infect
consid
subsequ
rv
detect
nonident
identifi
least
day
follow
previou
episod
ident
rv
presenc
copathogen
defin
bacteri
fungal
nonrespiratori
viru
pathogen
isol
respiratori
tract
sampl
episod
infect
overal
mortal
defin
death
due
caus
within
day
vrti
diagnosi
allohsct
death
attribut
vrti
defin
death
result
respiratori
failur
caus
exclud
risk
vrti
calcul
number
patient
test
posit
rv
among
allohsct
recipi
patient
baselin
characterist
compar
vrti
statu
use
chisquar
test
fisher
exact
test
categor
variabl
student
test
wilcoxon
ranksum
test
continu
variabl
first
episod
vrti
consid
risk
factor
analysi
univari
multivari
analys
risk
factor
vrti
perform
use
logist
regress
model
variabl
p
valu
includ
multivari
test
along
variabl
previous
identifi
import
risk
factor
vrti
includ
lymphopenia
gvhd
donor
relat
patient
vrti
record
review
day
follow
infect
patient
without
vrti
review
censor
date
deathicu
admiss
day
follow
transplant
whichev
sooner
surviv
death
icu
admiss
within
day
follow
transplant
assess
use
kaplanmei
plot
stratifi
vrti
statu
logrank
test
use
assess
differ
surviv
among
group
statist
analys
perform
use
r
version
statist
signific
defin
approv
conduct
studi
grant
melbourn
health
human
research
ethic
committe
refer
total
patient
identifi
review
period
januari
decemb
medic
record
could
obtain
patient
includ
patient
vrti
figur
patient
review
includ
slightli
male
n
femal
n
median
patient
age
year
interquartil
rang
iqr
year
median
age
patient
vrti
significantli
lower
patient
without
p
patient
demograph
data
characterist
significantli
differ
vrti
statu
tabl
patient
test
vrti
within
day
follow
allohsct
episod
vrti
identifi
patient
eight
patient
multipl
episod
episod
episod
median
time
onset
first
infect
date
allohsct
day
iqr
day
among
patient
identifi
vrti
first
episod
identifi
first
day
follow
transplant
clinic
characterist
vrti
episod
summar
tabl
rhinoviru
account
major
infect
episod
follow
rsv
episod
coinfect
pathogen
case
initi
present
urti
pronounc
rsv
progress
lrti
observ
patient
initi
present
urti
common
rhinoviru
common
symptom
observ
cough
n
follow
fever
coryza
sputum
product
rate
cough
versu
sputum
product
versu
fever
versu
significantli
higher
patient
lrti
compar
urti
p
antivir
therapi
administ
case
among
patient
rsv
urti
lrti
receiv
ribavirin
urti
receiv
either
placebo
part
clinic
trial
patient
either
influenza
b
receiv
oseltamivir
patient
lrti
rhinoviru
infect
n
receiv
iv
immunoglobulin
antivir
therapi
initi
within
median
day
iqr
day
detect
rv
median
durat
antivir
therapi
day
iqr
day
sixteen
copathogen
identifi
vrti
episod
one
episod
copathogen
bacteri
fungal
episod
copathogen
episod
fungal
pathogen
episod
bacteri
fungal
pathogen
bacteri
copathogen
found
episod
account
onehalf
copathogen
detect
includ
staphylococcu
spp
n
enterococcu
faecium
n
haemophilu
influenza
n
chlamydophila
pneumonia
n
pseudomona
aeruginosa
n
note
fungal
nonrespiratori
viru
copathogen
found
concomitantli
rhinoviru
infect
fungal
copathogen
identifi
includ
aspergillu
n
candida
albican
n
cladosporium
sp
n
saccharomyc
cervisia
n
p
jirovecii
n
episod
met
european
organ
research
treatment
cancermycos
studi
group
criteria
invas
fungal
diseas
nonrespiratori
virus
isol
cmv
univari
multivari
analys
previou
autolog
hsct
associ
increas
risk
vrti
odd
ratio
confid
interv
variabl
includ
age
sex
underli
diseas
cmv
seroposit
donor
relat
stem
cell
sourc
condit
regimen
intens
acut
gvhd
lymphopenia
neutropenia
statist
signific
tabl
addit
variabl
significantli
associ
risk
vrti
fix
period
follow
hsct
day
day
day
follow
transplant
total
episod
vrti
studi
cohort
studi
period
episod
associ
icu
admiss
within
day
vrti
episod
necessit
use
mechan
ventil
episod
episod
vrti
rhinoviru
rsv
influenza
lrti
initi
present
respiratori
symptom
precipit
icu
admiss
patient
admit
icu
within
median
day
iqr
day
vrti
median
durat
day
iqr
day
risk
icu
admiss
within
day
follow
transplant
patient
vrti
without
vrti
significantli
differ
p
figur
five
patient
die
within
day
vrti
rhinoviru
infect
prior
icu
admiss
three
patient
admit
icu
day
detect
rhinoviru
wherea
patient
icu
admiss
day
day
follow
detect
rhinoviru
patient
die
lrti
initi
site
infect
copathogen
detect
howev
none
death
directli
attribut
vrti
caus
death
includ
multiorgan
failur
n
pneumon
n
acut
pulmonari
edema
n
aspir
pneumonia
gvhd
fluid
overload
n
risk
mortal
within
day
follow
transplant
patient
vrti
without
vrti
significantli
differ
p
figur
vrti
patient
die
within
day
follow
transplant
develop
vrti
first
day
follow
transplant
studi
vrti
preval
among
allohsct
recipi
first
day
follow
transplant
frequenc
vrti
among
allohsct
recipi
consist
rate
report
elsewher
howev
differ
studi
previou
studi
includ
shorter
durat
review
day
inclus
symptomat
patient
rang
pathogen
test
outcom
icu
admiss
death
day
follow
transplant
rhinoviru
account
major
infect
report
previous
albeit
among
symptomat
asymptomat
patient
copathogen
identifi
episod
common
patient
rhinoviru
infect
ison
et
al
hypothes
rhinoviru
might
predispos
patient
addit
infect
respiratori
colon
potenti
pathogen
bacteria
also
may
increas
risk
subsequ
vrti
howev
note
studi
present
studi
number
patient
small
investig
potenti
link
warrant
cohort
patient
undergon
previou
autohsct
increas
risk
develop
vrti
independ
gvhd
donor
relat
lymphopenia
autohsct
identifi
import
risk
factor
progress
lrti
previou
autohsct
may
reflect
advanc
diseas
statu
thu
suscept
patient
vrti
addit
cumul
immun
suppress
multipl
line
previou
therapi
may
increas
risk
vrti
seen
patient
multipl
myeloma
delay
immun
recoveri
follow
autohsct
also
could
explain
increas
risk
vrti
patient
popul
key
find
present
studi
low
number
death
patient
vrti
mortal
directli
attribut
vrti
find
consist
rate
report
previou
studi
unabl
directli
assess
factor
contribut
reduc
mortal
postul
may
attribut
high
standard
support
care
addit
antivir
therapi
initi
rsv
case
episod
influenza
type
b
infect
earli
cours
infect
among
patient
vrti
death
occur
patient
acquir
infect
within
day
transplant
high
risk
poor
prognosi
subgroup
support
need
strict
infect
prevent
measur
staff
patient
earli
day
transplant
along
care
assess
patient
present
allohsct
respiratori
symptom
studi
demonstr
vrti
import
caus
morbid
allohsct
recipi
vrti
episod
necessit
icu
admiss
requir
use
mechan
ventil
percentag
consist
previou
report
overal
close
patient
lrti
initi
present
progress
lrti
occur
infect
commonli
involv
rhinoviru
progress
lrti
also
observ
rsv
urti
episod
higher
rate
report
previous
innat
adapt
arm
immun
system
particularli
neutrophil
cytotox
cell
play
integr
role
defens
vrti
respons
includ
episod
rsv
rhinoviru
detect
concurr
percentag
sum
episod
rhinoviru
infect
identifi
neither
urti
lrti
insuffici
inform
avail
classif
nonattribut
death
calcul
use
number
patient
mediat
appear
protect
role
rsv
infect
wherea
respons
may
associ
sever
diseas
manifest
profound
immun
deplet
impair
immun
respons
seen
acut
period
follow
transplant
could
account
rate
initi
lrti
progress
seen
even
respiratori
virus
consid
less
pathogen
rhinovirus
addit
cohort
lower
rate
antivir
therapi
rsv
evalu
pulmonari
function
test
result
risk
vrti
later
complic
airway
diseas
shown
previous
erard
et
al
could
assess
limit
studi
number
rv
includ
multiplex
pcr
panel
rv
parainfluenza
viru
adenoviru
coronaviru
hmpv
routin
test
might
import
caus
morbid
patient
rhinoviru
caus
vrti
burden
studi
may
overestim
furthermor
studi
examin
preval
risk
factor
outcom
vrti
within
day
follow
transplant
result
might
translat
beyond
time
frame
howev
known
highrisk
period
studi
focus
time
frame
highlight
import
earli
prevent
measur
infect
control
measur
among
patient
well
healthcar
worker
follow
transplant
conclus
vrti
preval
among
allohsct
recipi
although
impact
mortal
appear
limit
led
number
icu
admiss
necessit
use
mechan
ventil
sever
case
find
indic
associ
previou
autohsct
increas
risk
vrti
outcom
poorest
patient
diagnos
within
day
follow
transplant
group
patient
high
risk
poor
prognosi
earli
prevent
infect
control
measur
target
author
thank
ms
jenni
collin
assist
transplantationrel
data
staff
melbourn
health
share
patholog
servic
patholog
inform
aspergillu
pcr
test
perform
depart
microbiolog
westmead
hospit
financi
disclosur
world
health
organ
collabor
centr
refer
research
influenza
support
australian
govern
depart
conflict
interest
statement
conflict
interest
report
